Kat J. McAlpine
Kat J. McAlpine is a freelance science writer. She is head of science communications at Felix Creative, a Boston-based content agency.
Pharmaceutical manufacturers are working to expand access to CAR T clinical trials by partnering with hospitals like BMC that care for racially diverse patients.
CAR T, a personalized cell therapy, has been a game-changer for certain blood cancers, but its high cost has been a huge barrier to equitable access.